ABSTRACT

Examining the Impact of Voluntarily Restricted Distribution Systems in the Pharmaceutical Supply Chain, Hearing Before the Subcommittee on Health Care, Benefits, and Administrative Rules, of the Committee on Oversight and Government Reform, United States House of Representatives, One Hundred Fifteenth Congress, First Session, March 22, 2017   [open pdf - 1MB]

This testimony compilation made by the HSDL staff is from the March 22, 2017 hearing "Examining the Impact of Voluntarily Restricted Distribution Systems in the Pharmaceutical Supply Chain," held before the United States House of Representatives Subcommittee on Health Care, Benefits, and Administrative Rules of the Committee on Oversight and Government Reform. The purpose of this hearing was to "discuss the purpose of using voluntary restricted distribution systems in the pharmaceutical supply chain […] [and] […] examine how a manufacturer may use a restricted distribution system to delay or block generic competition." Statements, letters, and materials submitted for the record include those of the following: Bruce Leicher, Gerard Anderson, and David Mitchell.

Publisher:
Date:
2017-03-22
Copyright:
Public Domain
Retrieved From:
Committee on Oversight and Government Reform: https://oversight.house.gov/
Format:
pdf
Media Type:
application/pdf
URL:
Help with citations